Remicade Side Effects, Infusion Time, and What to Expect

Remicade (infliximab) is an intravenous biologic that treats Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis. Infusions typically take about two hours, with potential side effects including infusion reactions, increased infection risk, and required tuberculosis screening before starting treatment.

Few biologic medications have the track record of Remicade. First approved by the FDA in 1998 for Crohn’s disease, infliximab has since earned approvals for six distinct inflammatory conditions, making it one of the most broadly prescribed infusion therapies in the world. That versatility comes with complexity, though. Understanding what Remicade does in the body, what side effects to watch for, and how it stacks up against newer biosimilar alternatives can help patients feel more prepared at every stage of treatment.

What Is Remicade and How Does It Work?

Remicade belongs to a class of drugs called TNF-alpha inhibitors. TNF-alpha (tumor necrosis factor-alpha) is a protein the immune system produces to drive inflammation. In autoimmune conditions, the body makes too much TNF-alpha, which damages healthy tissue. Infliximab is a monoclonal antibody, a lab-made protein that binds directly to TNF-alpha and blocks it from triggering inflammation.

Because Remicade is a large protein molecule, it cannot be absorbed through the digestive system. That is why it must be given as an intravenous (IV) infusion directly into the bloodstream. Learn more about how infusion therapy works and what to expect during treatment.

Conditions Treated with Remicade

Remicade is FDA-approved for the following conditions in adults:

• Crohn’s disease — moderate to severe, including fistulizing Crohn’s
• Ulcerative colitis (UC) — moderate to severe, when other treatments have not worked
• Rheumatoid arthritis (RA) — in combination with methotrexate
• Psoriatic arthritis
• Plaque psoriasis — chronic, severe cases
• Ankylosing spondylitis (AS) — a type of inflammatory spinal arthritis

It is also approved for children ages 6 and older with Crohn’s disease or ulcerative colitis. The Crohn’s & Colitis Foundation notes that biologic therapies like infliximab have significantly changed outcomes for pediatric IBD patients.

The Remicade Infusion Process

Remicade is dosed based on body weight, typically at 5 mg/kg (milligrams per kilogram). For RA patients, the dose may be increased up to 10 mg/kg. The standard schedule follows a loading phase and maintenance phase:

The standard Remicade infusion time is about two hours, though some patients who tolerate infusions well may be eligible for shortened infusions of approximately one hour after several uneventful treatments. A post-infusion observation period of at least 30 minutes is typical. Most patients spend roughly 2.5 to 3 hours at each appointment when accounting for vitals, setup, and monitoring.

Remicade Side Effects

Like all biologic medications, Remicade carries side effects. The most common ones reported in clinical trials include:

• Upper respiratory infections (colds, sinus infections)
• Headache
• Nausea
• Abdominal pain
• Fatigue
• Infusion reactions (flushing, shortness of breath, chest tightness, low blood pressure)

Infusion Reactions

Infusion reactions are among the most discussed Remicade side effects. According to Mayo Clinic, these reactions occur in roughly 10% to 20% of patients during or shortly after infusion. Symptoms can range from mild (itching, flushing) to more serious (chest tightness, difficulty breathing, significant drops in blood pressure). Premedication with acetaminophen, diphenhydramine (Benadryl), or corticosteroids often helps prevent or reduce these reactions.

Patients who develop antibodies to infliximab (sometimes called anti-drug antibodies) face higher risk of infusion reactions over time. This is one reason many prescribers recommend taking an immunomodulator like methotrexate or azathioprine alongside Remicade, as it can reduce antibody formation.

Serious Risks and Safety Warnings

Before beginning Remicade, prescribers will order a tuberculosis (TB) screening test. Infliximab suppresses TNF-alpha, which plays a role in keeping latent TB infections dormant. Without screening, a hidden TB infection can reactivate and become life-threatening.

Other serious risks include:

• Hepatitis B reactivation — screening is required before treatment
• Heart failure worsening — Remicade is contraindicated at doses above 5 mg/kg in patients with moderate to severe heart failure
• Liver injury — rare cases of severe hepatic reactions have been reported
• Nervous system problems — including demyelinating disorders resembling multiple sclerosis

Patients should report any signs of infection (fever, persistent cough, wounds that do not heal) or unusual symptoms to their healthcare provider immediately. Understanding your insurance coverage for infusion therapies can also help you plan for the ongoing monitoring that Remicade requires.

Remicade vs. Biosimilars: Inflectra, Renflexis, and Avsola

Several biosimilar versions of infliximab are now available in the United States. A biosimilar is a biologic medication that is highly similar to an already-approved reference product, with no clinically meaningful differences in safety or effectiveness. Current infliximab biosimilars include:

The FDA’s interchangeability designation means a pharmacist can substitute a biosimilar for Remicade without needing additional prescriber approval, similar to how generic drugs work.

Addressing Biosimilar Switch Anxiety

Being told by an insurer or prescriber that it is time to switch from Remicade to a biosimilar can feel unsettling, especially for patients who have been stable for years. This reaction is completely understandable. Research published in major gastroenterology journals shows that switching from Remicade to an infliximab biosimilar does not increase the rate of side effects, loss of response, or infusion reactions compared to staying on the original.

One factor to be aware of: the “nocebo effect.” Studies have found that some patients who switch experience new symptoms driven by negative expectations rather than the medication itself. Knowing this can help patients distinguish between genuine side effects and anxiety-related symptoms. If symptoms arise after a switch, they should still be reported to a healthcare provider for proper evaluation.

Remicade Infusion Cost and Insurance

Remicade is among the more expensive biologic therapies. Without insurance, a single infusion can cost between $3,000 and $10,000 or more, depending on the patient’s weight-based dose and the infusion site. Annual costs can exceed $25,000 to $40,000.

Most commercial insurance plans and Medicare Part B cover Remicade when it is deemed medically necessary. However, many insurers now require step therapy or prefer biosimilar alternatives before approving brand-name Remicade. Patients facing coverage challenges may benefit from manufacturer copay assistance programs or independent patient assistance foundations.

Home Infusion Options

An increasing number of patients are receiving Remicade through home infusion services. Home infusion can reduce travel time, offer more flexible scheduling, and provide a more comfortable environment. A registered nurse administers the infusion at the patient’s home using the same protocols as an outpatient center.

Not every patient is a candidate for Remicade home infusion. Most providers require several successful infusions in a clinical setting first to ensure the patient tolerates the medication well. Patients with a history of infusion reactions may need to continue receiving treatment in a supervised setting.